Abstract
The importance of paradigms for guiding scientific research is explained with reference to the seminal work of Karl Popper and Thomas Kuhn. A prevalent paradigm, followed for more than a decade in HIV-1 vaccine research, which gave rise to the strategy known as structure-based reverse vaccinology is described in detail. Several reasons why this paradigm did not allow the development of an effective HIV-1 vaccine are analyzed. A major reason is the belief shared by many vaccinologists that antibodies possess a narrow specificity for a single epitope and are not polyspecific for a diverse group of potential epitopes. When this belief is abandoned, it becomes obvious that the one particular epitope structure observed during the crystallographic analysis of a neutralizing antibody-antigen complex does not necessarily reveal, which immunogenic structure should be used to elicit the same type of neutralizing antibody. In the physical sciences, scientific explanations are usually presented as logical deductions derived from a relevant law of nature together with certain initial conditions. In immunology, causal explanations in terms of a single cause acting according to a law of nature are not possible because numerous factors always play a role in bringing about an effect. The implications of this state of affairs for the rational design of HIV vaccines are outlined. An alternative approach to obtain useful scientific understanding consists in intervening empirically in the immune system and it is suggested that manipulating the system experimentally is needed to learn to control it and achieve protective immunity by vaccination.
It makes no sense to do the same thing over and over again and expect a different result.
Albert Einstein
Frontiers in Immunology, 2014, 5, 593.
Marc H V Van Regenmortel
Copyright: © 2014 Van Regenmortel
This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/legalcode)
To view the original article, visit https://www.frontiersin.org/articles/10.3389/fimmu.2014.00593/full
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Alberts B, Kirschner MW, Tilghman S, Varmus H. Rescuing US biomedical research from its systemic flaws. Proc Natl Acad Sci U S A. 2014;111:5773–7. https://doi.org/10.1073/pnas.1404402111.
Berek C, Milstein C. Mutation drift and repertoire shift in the maturation of the immune response. Immunol Rev. 1987;96:23–41. https://doi.org/10.1111/j.1600-065X.1987.tb00507.x.
Berzofsky JA. Intrinsic and extrinsic factors in protein antigenic structure. Science. 1985;229:932–40.
Bird A. Thomas Kuhn. In: Zalta EN, editor. The Stanford Encyclopedia of Philosophy (Winter 2018 Edition); 2018. https://plato.stanford.edu/archives/win2018/entries/thomas-kuhn/
Bosshard HR. Molecular recognition by induced fit: how fit is the concept? News Physiol Sci. 2001;16:171–3.
Burton DR. Antibodies, viruses and vaccines. Nat Rev Immunol. 2002;2:706–13.
Burton DR. Scaffolding to build a rational vaccine design strategy. Proc Natl Acad Sci U S A. 2010;107:17859–60.
Burton DR, Weiss RA. AIDS/HIV. A boost for HIV vaccine design. Science. 2010;329:770–3. https://doi.org/10.1126/science.1194693.
Burton DR, Pyati J, Koduri R, Sharp SJ, Thornton GB, Parren PW, et al. Efficient isolates of HIV-1 by a recombinant human monoclonal neutralization of primary antibody. Science. 1994;266:1024–7. https://doi.org/10.1126/science.7973652.
Burton DR, Stanfield RL, Wilson IA. Antibody vs HIV in a clash of evolutionary titans. Proc Natl Acad Sci U S A. 2005;102:14943–8.
Burton DR, Ahmed R, Barouch DH, Butera ST, Crotty S, Godzik A, Kaufmann DE, McElrath MJ, Nussenzweig MC, Pulendran B, et al. A blueprint for HIV vaccine discovery. Cell Host Microbe. 2012;12:396–407.
Chatellier J, Van Regenmortel MHV, Vernet T, Altschuh D. Functional mapping of conserved residues located at the VL and VH domain interface of a Fab. J Mol Biol. 1996;264:1–6. https://doi.org/10.1006/jmbi.1996.0618.
Chen ZJ, Wheeler CJ, Shi W, Wu AJ, Yarboro CH, Gallagher M, et al. Polyreactive antigen-binding B cells are the predominant cell type in the newborn B cell repertoire. Eur J Immunol. 1998;28:989–94. https://doi.org/10.1002/(SICI)1521-4141(199803)28:03<989::AID-IMMU989>3.0.CO;2-1.
Chen W, Streaker ED, Russ DE, Feng Y, Prabakaran P, Dimitrov D. Characterization of germline antibody libraries from human umbilical cord blood and selection of monoclonal antibodies to viral envelope glycoproteins: implications for mechanisms of immune evasion and design of vaccine immunogens. Biochem Biophys Res Commun. 2012;417:1164–9.
Cohen IR, Hershberg U, Solomon S. Antigen-receptor degeneracy and immunological paradigms. Mol Immunol. 2004;40:993–6.
Corti D, Lanzavecchia A. Broadly neutralizing antiviral antibodies. Annu Rev Immunol. 2013;31:705–42. https://doi.org/10.1146/annurev-immunol-032712-095916.
Cunningham BC, Wells JA. Comparison of a structural and a functional epitope. J Mol Biol. 1993;234:554–63. https://doi.org/10.1006/jmbi.1993.1611.
Dimitrov DS. Therapeutic antibodies, vaccines and antibodyomes. MAbs. 2010;2:347–56.
Diskin R, Scheid JF, Marcovecchio PM, West AP Jr, Klein F, Gao H, Gnanapragasam PN, Abadir A, Seaman MS, Nussenzweig MC, et al. Increasing the potency and breadth of an HIV antibody by using structure-based rational design. Science. 2011;334:1289–93.
Doria-Rose NA. HIV neutralizing antibodies: clinical correlates and implications for vaccines. J Infect Dis. 2010;201:981–3. https://doi.org/10.1086/651143.
Doria-Rose NA, Klein RM, Daniels MG, O’Dell S, Nason M, Lapedes A, et al. Breadth of human immunodeficiency virus-specific neutralizing activity in sera: clustering analysis and association with clinical variables. J Virol. 2010;84:1631–6. https://doi.org/10.1128/JVI.01482-09.
Douek DC, Kwong PD, Nabel GJ. The rational design of an AIDS vaccine. Cell. 2006;124:677–81.
Dupré J. The disorder of things. Metaphysical foundations of the disunity of science. Cambridge, MA: Harvard University Press; 1993.
Eisen HN, Chakraborty AK. Evolving concepts of specificity in immune reactions. Proc Natl Acad Sci U S A. 2010;107:22373–80. https://doi.org/10.1073/pnas.1012051108.
Esparza J. The global HIV vaccine enterprise. Int Microbiol. 2005;8:93–101.
Esparza J. What has 30 years of HIV research taught us? Vaccine. 2013b;1:513–26.
Euler Z, van Gils MJ, Bunnik EM, Phung P, Schweighardt B, Wrin T, et al. Cross-reactive neutralizing humoral immunity does not protect from HIV type 1 disease progression. J Infect Dis. 2010;201:1045–53. https://doi.org/10.1086/651144.
Euler Z, Bunnik EM, Burger JA, Boeser-Nunnink BD, Grijsen ML, Prins JM, et al. Activity of broadly neutralizing antibodies, including PG9, PG16, and VRC01, against recently transmitted subtype B HIV-1 variants from early and late in the epidemic. J Virol. 2011;85:7236–45. https://doi.org/10.1128/JVI.00196-11.
Euler Z, van den Kerkhof TL, van Gils MJ, Burger JA, Edo-Matas D, Phung P, et al. Longitudinal analysis of early HIV-1-specific neutralizing activity in an elite neutralizer and in five patients who developed cross-reactive neutralizing activity. J Virol. 2012;86:2045–55. https://doi.org/10.1128/JVI.06091-11.
Fauci AS, Marston HD. Ending AIDS – is an HIV vaccine necessary? N Engl J Med. 2014;370:495–8. https://doi.org/10.1056/NEJMp1313771.
Van Fraassen BC. Experience. In: The empirical stance. New Haven, CT: Yale University Press; 2002. p. 111–52.
Gannon F. Too complex to comprehend? EMBO Rep. 2007;8:705.
Gray ES, Madiga MC, Hermanus T, Moore PL, Wibmer CK, Tumba NL, et al. The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4+ T cell decline and high viral load during acute infection. J Virol. 2011;85:4828–40. https://doi.org/10.1128/JVI.00198-11.
Greenspan NS, Di Cera E. Defining epitopes: it’s not as easy as it seems. Nat Biotechnol. 1999;17:936–7. https://doi.org/10.1038/13590.
Gunawardena J. Models in biology: ‘accurate descriptions of our pathetic thinking’. BMC Biol. 2014;12:29. https://doi.org/10.1186/1741-7007-12-29.
Hacking I. Representing and intervening. Princeton, NJ: Cambridge University Press; 1983. p. 1–304.
Haynes BF, Moody MA, Verkoczy L, Kelsoe G, Alam SM. Antibody polyspecificity and neutralization of HIV-1: a hypothesis. Hum Antibodies. 2005b;14:59–67.
Haynes BF, Kelsoe G, Harrison SC, Kepler TB. B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study. Nat Biotechnol. 2012a;30:423–33. https://doi.org/10.1038/nbt.2197.
Ho J, Uger RA, Zwick MB, Luscher MA, Barber BH, MacDonald KS. Conformational constraints imposed on a pan-neutralizing HIV-1 antibody epitope result in increased antigenicity but not neutralizing response. Vaccine. 2005;23:1559–73. https://doi.org/10.1016/j.vaccine.2004.09.037.
Hofmann-Lehmann R, Vlasak J, Rasmussen RA, Smith BA, Baba TW, Liska V, et al. Postnatal passive immunization of neonatal macaques with a triple combination of human monoclonal antibodies against oral simian-human immunodeficiency virus challenge. J Virol. 2001;75:7470–80. https://doi.org/10.1128/JVI.75.16.7470-7480.2001.
Horgan J. The end of science. New York: Broadway Books; 1996. p. 41–7.
Horgan J. The end of science. New York: Broadway Books; 2006. p. 32–41.
Jardine J, Julien JP, Menis S, Ota T, Kalyuzhniy O, McGuire A, et al. Rational HIV immunogen design to target specific germline B cell receptors. Science. 2013;340:711–6. https://doi.org/10.1126/science.1234150.
Joyce JG, Hurni WM, Bogusky MJ, Garsky VM, Liang X, Citron MP, et al. Enhancement of alpha-helicity in the HIV-1 inhibitory peptide DP178 leads to an increased affinity for human monoclonal antibody 2F5 but does not elicit neutralizing responses in vitro. Implications for vaccine design. J Biol Chem. 2002;277:45811–20. https://doi.org/10.1074/jbc.M205862200.
Karlsson-Hedestam GB, Fouchier RA, Phogat S, Burton DR, Sodroski J, Wyatt RT. The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus. Nat Rev Microbiol. 2008;6:143–55. https://doi.org/10.1038/nrmicro1819.
Kelley L, Scott M. The evolution of biology. A shift towards the engineering and prediction-generating tools and away from traditional research practice. EMBO Rep. 2008;9:1163–7.
Klein F, Halper-Stromberg A, Horwitz JA, Gruell H, Scheid JF, Bournazos S, et al. HIV therapy by a combination of broadly neutralizing antibodies in humanized mice. Nature. 2012;492:118–22. https://doi.org/10.1038/nature11604.
Klein F, Diskin R, Scheid JF, Gaebler SC, Mouquet H, Georgiev IS, Pancera M, Zhou T, Incesu R-B, Fu BZ, et al. Somatic mutations of the immunoglobulin framework are generally required for broad and potent HIV-1 neutralization. Cell. 2013;153:126–38.
Kong L, Sattentau QJ. Antigenicity and immunogenicity in HIV-1 antibody-based vaccine design. J AIDS Clin Res. 2012. https://doi.org/10.4172/2155-6113.
Kuhn TS. The structure of scientific revolutions. Chicago, IL: University of Chicago Press; 1962. p. 1–264.
Kuntz ID. Structure-based strategies for drug design and discovery. Science. 1992;257:1078–82.
Laal S, Burda S, Gorny MK, Karwowska S, Buchbinder A, Zolla-Pazner S. Synergistic neutralization of human immunodeficiency virus type 1 by combinations of human monoclonal antibodies. J Virol. 1994;68:4001–8.
Leonelli S. Understanding in biology: the impure nature of biological knowledge. In: De Regt HW, Leonelli S, Eigner K, editors. Scientific understanding. Pittsburgh: University of Pittsburgh Press; 2009. p. 189–209.
Liao HX, Lynch R, Zhou T, Gao F, Alam SM, Boyd SD, et al. Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. Nature. 2013a;496:469–76. https://doi.org/10.1038/nature12053.
Lipton P. What good is an explanation? In: Cornwell J, editor. Explanations. Styles of explanation in science. Oxford: Oxford University Press; 2004. p. 1–21.
Manivel V, Bayiroglu F, Siddiqui Z, Salunke DM, Rao KV. The primary antibody repertoire represents a linked network of degenerate antigen specificities. J Immunol. 2002;169:888–97.
Mariuzza RA. Multiple paths to multispecificity. Immunity. 2006;24:359–61.
Mascola JR. HIV/AIDS: allied responses. Natuzwickre. 2007;449:29–30. https://doi.org/10.1038/449029a.
Mascola JR, Montefiori DC. The role of antibodies in HIV vaccines. Annu Rev Immunol. 2010;28:413–44.
Mascola JR, Lewis MG, Stiegler G, Harris D, VanCott TC, Hayes D, et al. Protection of macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J Virol. 1999;73:4009–18.
McLellan JS, Chen M, Joyce MG, Sastry M, Stewart-Jones GB, Yang Y, et al. Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus. Science. 2013;342:592–8. https://doi.org/10.1126/science.1243283.
Montero M, van Houten NE, Wang X, Scott JK. The membrane-proximal external region of the human immunodeficiency virus type 1 envelope: dominant site of antibody neutralization and target for vaccine design. Microbiol Mol Biol Rev. 2008;72:54–84. https://doi.org/10.1128/MMBR.00020-07.
Moudgil KD, Sercarz EE, Grewal IS. Modulation of the immunogenicity of antigenic determinants by their flanking residues. Immunol Today. 1998;19:217–20. https://doi.org/10.1016/S0167-5699(97)01233-4.
Mouquet H, Nussenzweig MC. Polyreactive antibodies in adaptive immune responses to viruses. Cell Mol Life Sci. 2012;69:1435–45.
Mouquet H, Nussenzweig MC. HIV: roadmaps to a vaccine. Nature. 2013;496:441–2. https://doi.org/10.1038/nature12091.
Nabel GJ, Kwong PD, Mascola JR. Progress in the rational design of an AIDS vaccine. Philos Trans R Soc Lond B Biol Sci. 2011;366:2759–65.
Notkins AL. Polyreactivity of antibody molecules. Trends Immunol. 2004;25:174–9.
Parnes O. From interception to incorporation: degeneracy and promiscuous recognition as precursors of a paradigm shift in immunology. Mol Immunol. 2004;40:985–91.
Pejchal R, Wilson IA. Structure-based vaccine design in HIV: blind men and the elephant? Curr Pharm Des. 2010;16:3744–53.
Popper K. The logic of scientific discovery. London: Hutchinson; 1959. p. 1–513.
Prabakaran P, Chen W, Dimitrov DS. The antibody germline/maturation hypothesis, elicitation of broadly neutralizing antibodies against HIV-1 and cord blood IgM repertoires. Front Immunol. 2014;5:398.
Rappuoli R. Reverse vaccinology, a genome-based approach to vaccine development. Vaccine. 2001;19:2688–91.
Rappuoli R, Bagnoli F. Vaccine design: innovative approaches and novel strategies. Norfolk: Caister Academic Press; 2011.
Salmon WC. Causality and explanation. Oxford: Oxford University Press; 1998.
Sattentau QJ, McMichael AJ. New templates for HIV-1 antibody-based vaccine design. F1000 Biol Rep. 2010;2:60. https://doi.org/10.3410/b2-60.
Scheid JF, Mouquet H, Feldhahn N, Seaman MS, Velinzon K, Pietzsch J, Ott RG, Anthony RM, Zebroski H, Hurley A, et al. Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature. 2009;458:636–40.
Schiffner T, Sattentau QJ, Dorrell L. Development of prophylactic vaccines against HIV-1. Retrovirology. 2013;10:72. https://doi.org/10.1186/1742-4690-10-72.
Schildbach JF, Near RI, Bruccoleri RE, Haber E, Jeffrey PD, Novotny J, et al. Modulation of antibody affinity by a non-contact residue. Protein Sci. 1993;2:206–14. https://doi.org/10.1002/pro.5560020209.
Sok D, Doores KJ, Briney B, Le KM, Saye-Francisco KL, Ramos A, et al. Promiscuous glycan site recognition by antibodies to the high-mannose patch of gp120 broadens neutralization of HIV. Sci Transl Med. 2014;6:236ra63. https://doi.org/10.1126/scitranslmed.3008104.
Sperling R, Francus T, Siskind GW. Degeneracy of antibody specificity. J Immunol. 1983;131:882–5.
Stamatatos L, Morris L, Burton DR, Mascola JR. Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine? Nat Med. 2009;15:866–70. https://doi.org/10.1038/nm.1949.
Sundberg EJ, Mariuzza RA. Molecular recognition in antibody-antigen complexes. Adv Protein Chem. 2002;61:119–60.
van Gils MJ, Bunnik EM, Burger JA, Jacob Y, Schweighardt B, Wrin T, et al. Rapid escape from preserved cross-reactive neutralizing humoral immunity without loss of viral fitness in HIV-1-infected progressors and long-term non progressors. J Virol. 2010;84:3576–85. https://doi.org/10.1128/JVI.02622-09.
Van Regenmortel MHV. Molecular design versus empirical discovery in peptide-based vaccines. Coming to terms with fuzzy recognition sites and ill-defined structure-function relationships in immunology. Vaccine. 1999b;18:216–21. https://doi.org/10.1016/S0264-410X(99)00192-9.
Van Regenmortel MHV. Reductionism and the search for structure-function relationships in antibody molecules. J Mol Recognit. 2002a;15:240–7.
Van Regenmortel MHV. Reductionism and complexity in molecular biology. EMBO J. 2004b;5:1016–20.
Van Regenmortel MHV. The rational design of biological complexity: a deceptive metaphor. Proteomics. 2007;7:965–75.
Van Regenmortel MHV. Synthetic peptide vaccines and the search for neutralization of B cell epitopes. Open Vaccine J. 2009a;2:33–44. https://doi.org/10.2174/1875035401002010033.
Van Regenmortel MHV. Two meanings of reverse vaccinology and the empirical nature of vaccine science. Vaccine. 2011a;29:7875.
Van Regenmortel MHV. Limitations to the structure-based design of HIV-1 vaccine immunogens. J Mol Recognit. 2011b;24:741–53.
Van Regenmortel MHV. Requirements for empirical immunogenicity trials, rather than structure-based design, for developing an effective HIV vaccine. Arch Virol. 2012a;157:1–20.
Van Regenmortel MHV. Basic research in HIV vaccinology is hampered by reductionist thinking. Front Immunol. 2012b;3:194. https://doi.org/10.3389/fimmu.2012.00194.
Van Regenmortel MHV. Specificity, polyspecificity, and heterospecificity of antibody-antigen recognition. J Mol Recognit. 2014a;27:627–39.
Van Regenmortel MHV, Hull D. Promises and limits of reductionism in the biomedical sciences. Chichester: Wiley; 2002. p. 1–377.
Van Regenmortel MHV, Andrieu JM, Dimitrov DS, Ensoli B, Hioe CE, Moog C, Ruprecht RM. Paradigm changes and the future of HIV vaccine research: a summary of a workshop held in Baltimore on 20 November 2013. J AIDS Clin Res. 2014;5:281. https://doi.org/10.4172/2155–6113.1000281.
Walker LM, Burton DR. Rational antibody-based HIV-1 vaccine design: current approaches and future directions. Curr Opin Immunol. 2010;22:358–66.
Walker LM, Phogat SK, Chan-Hui PY, Wagner D, Phung P, Goss JL, et al. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science. 2009;326:285–9. https://doi.org/10.1126/science.1178746.
Wilson IA, Stanfield RL. Antibody-antigen interactions: new structures and new conformational changes. Curr Opin Struct Biol. 1994;4:857–67.
Wu X, Yang ZY, Li Y, Hogerkorp CM, Schief WR, Seaman MS, Zhou T, Schmidt SD, Wu L, Xu L, et al. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science. 2010;329:856–61.
Wu X, Zhou T, Zhu J, Zhang B, Georgiev I, Wang C, et al. Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. Science. 2011b;333:1593–602. https://doi.org/10.1126/science.1207532.
Wucherpfennig KW, Allen PM, Celada F, Cohen IR, De Boer R, Garcia KC, Goldstein B, Greenspan R, Hafler D, Hodgkin P, et al. Polyspecificity of T cell and B cell receptor recognition. Semin Immunol. 2007;19:216–24.
Xiao X, Chen W, Feng Y, Zhu Z, Prabakaran P, Wang Y, Zhang MY, Longo NS, Dimitrov DS. Germline-like predecessors of broadly neutralizing antibodies lack measurable binding to HIV-1 envelope glycoproteins: implications for evasion of immune responses and design of vaccine immunogens. Biochem Biophys Res Commun. 2009;390:404–9.
Yin J, Beuscher AE IV, Andryski SE, Stevens RC, Schultz PG. Structural plasticity and the evolution of antibody affinity and specificity. J Mol Biol. 2003;330:651–6.
Ylikoski P. The illusion of depth of understanding in science. In: De Regt HW, Leonelli S, Eigner K, editors. Scientific understanding. Pittsburgh: University of Pittsburgh Press; 2009. p. 100–19.
Zhou ZH, Zhang Y, Hu YF, Wahl LM, Cisar JO, Notkins AL. The broad antibacterial activity of the natural antibody repertoire is due to polyreactive antibodies. Cell Host Microbe. 2007b;1:51–61.
Zhu Z, Bossart KN, Bishop KA, Crameri G, Dimitrov AS, McEachern JA, et al. Exceptionally potent cross-reactive neutralization of Nipah and Hendra viruses by a human monoclonal antibody. J Infect Dis. 2008a;197:846–53. https://doi.org/10.1086/528801.
Zhu Z, Qin HR, Chen W, Zhao Q, Shen X, Schutte R, et al. Cross-reactive HIV-1-neutralizing human monoclonal antibodies identified from a patient with 2F5-like antibodies. J Virol. 2011;85:11401–8. https://doi.org/10.1128/JVI.05312-11.
Zwick MB, Wang M, Poignard P, Stiegler G, Katinger H, Burton DR, et al. Neutralization synergy of human immunodeficiency virus type 1 primary isolates by cocktails of broadly neutralizing antibodies. J Virol. 2001b;75:12198–208. https://doi.org/10.1128/JVI.75.24.12198-12208.2001.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Van Regenmortel, M.H.V. (2019). An Outdated Notion of Antibody Specificity Is One of the Major Detrimental Assumptions of the Structure-Based Reverse Vaccinology Paradigm, Which Prevented It from Helping to Develop an Effective HIV-1 Vaccine. In: HIV/AIDS: Immunochemistry, Reductionism and Vaccine Design. Springer, Cham. https://doi.org/10.1007/978-3-030-32459-9_17
Download citation
DOI: https://doi.org/10.1007/978-3-030-32459-9_17
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-32458-2
Online ISBN: 978-3-030-32459-9
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)